Atea's New Drug Offers Hope Against Neglected Hepatitis E Virus

BOSTON, MA – February 24, 2026 – Atea Pharmaceuticals has unveiled promising preclinical data for a new oral antiviral, AT-587, positioning it as a potential first-ever approved treatment for the globally overlooked Hepatitis E virus (HEV). The results, presented at the prestigious Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, suggest the drug is significantly more potent than current off-label options, offering a glimmer of hope for thousands of vulnerable patients.

A Silent Threat with No Approved Defense

Hepatitis E is a major public health concern that often flies under the radar. The World Health Organization estimates 20 million new infections occur annually, leading to tens of thousands of deaths. While the virus typically causes a self-limiting acute illness in healthy individuals, it poses a mortal threat to the immunocompromised.

For patients with weakened immune systems—such as organ transplant recipients, individuals with hematologic cancers, or those living with HIV—an HEV infection can become chronic. In these vulnerable populations, the virus, particularly genotypes 3 and 4 prevalent in the US and Europe, can cause rapid progression to liver cirrhosis and failure within just three to five years.

Despite this severe risk, there is no approved antiviral therapy for HEV. Physicians are left to rely on off-label treatments, primarily the drug ribavirin, which comes with significant drawbacks. Its efficacy is limited, with viral clearance achieved in only about 80% of patients, and it carries a heavy burden of side effects. This therapeutic void has created a clear and urgent unmet medical need, leaving the most vulnerable patients with few effective options.

The Science of a Potent New Weapon

Atea's announcement at CROI 2026 signals a potential turning point. The data, detailed in a poster presentation led by virologist Dr. Qi Huang, showcased the powerful antiviral activity of two proprietary compounds, AT-587 and AT-2490, in laboratory studies.

The findings were striking: AT-587, which Atea has selected as its lead candidate for clinical development, was shown to be 30 to 150 times more potent at inhibiting HEV replication in vitro compared to ribavirin and sofosbuvir, another antiviral sometimes used off-label. The studies also confirmed that AT-587 effectively generates its active form within human liver cells—the primary site of HEV infection—without showing signs of toxicity at the tested concentrations.

“We are excited to share these preclinical results at CROI showing the potent activity and promising in vitro safety profiles of AT-2490 and AT-587, our HEV product candidate,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, in a statement. “With no antivirals currently marketed for HEV, AT-587 has the potential to address a significant unmet need for a treatment option for patients with chronic HEV infection who are immunocompromised or at high risk for rapid progression to cirrhosis.”

Interestingly, the research also indicated that the compound has a broad spectrum of activity, showing effectiveness against other RNA viruses, including flaviviruses, rubella, and chikungunya, hinting at the platform's wider potential.

A Strategic Expansion Beyond Hepatitis C

The move into Hepatitis E represents a calculated expansion for Atea, a company that has built its reputation and pipeline around a proprietary nucleos(t)ide drug development platform. This platform is the engine behind its lead program: a combination therapy of bemnifosbuvir and ruzasvir for Hepatitis C (HCV), which is currently in late-stage Phase 3 trials with results anticipated later this year.

By targeting HEV, the company is leveraging its deep expertise in liver diseases and antiviral chemistry to tackle a new challenge. This diversification could prove strategically vital, opening up a new market where Atea could establish a first-mover advantage. The company estimates the potential commercial market for an effective HEV treatment in the U.S. and Europe to be between $750 million and $1 billion annually.

With a reported cash runway extending through 2027, Atea appears well-capitalized to fund the advancement of AT-587 into the clinic alongside its ongoing Phase 3 HCV program. This dual focus on major hepatitis viruses solidifies the company's ambition to become a leader in oral antiviral therapies for liver diseases.

Navigating the Path to Patients

The journey from a promising lab result to a widely available medicine is long and fraught with challenges, but the path for AT-587 is becoming clearer. Atea plans to initiate a Phase 1 clinical trial in mid-2026 to evaluate the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers.

Given the complete lack of approved treatments and the severity of chronic HEV in immunocompromised patients, AT-587 could be a candidate for expedited regulatory pathways. Programs like the FDA's Orphan Drug Designation or Accelerated Approval are designed for precisely this type of situation, where a novel drug addresses a serious condition with a high unmet need.

However, challenges remain. The true prevalence of chronic HEV is thought to be underestimated, partly due to a lack of standardized, widely available diagnostic tests in countries like the United States. This could complicate patient recruitment for clinical trials and initial market adoption. Atea's initial clinical efforts will be sharply focused on treating immunocompromised patients with chronic HEV genotypes 3 and 4, the primary culprits of chronic disease in developed nations.

The upcoming Phase 1 trial will be a critical first step. All eyes in the infectious disease and hepatology communities will be on Atea as it attempts to translate the remarkable potency seen in a petri dish into a safe and effective therapy that could finally offer a defense against this neglected virus.